Caribou Biosciences Reports Clinical Data From Dose Escalation Portion Of ANTLER Phase 1 Trial Showing 94% ORR, 69% CR Rate And 44% CR Rate At ≥6 Months Following Single Dose
Portfolio Pulse from Benzinga Newsdesk
Caribou Biosciences has reported clinical data from the dose escalation portion of its ANTLER Phase 1 trial. The data shows a 94% overall response rate, a 69% complete response rate, and a 44% complete response rate at 6 months or more following a single dose of CB-010. The longest complete response maintained to date is 24 months. The LBCL patient subgroup had a 50% complete response rate at 6 months or more, with the longest LBCL subgroup complete response maintained to date being 18 months.
July 13, 2023 | 8:02 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Caribou Biosciences' ANTLER Phase 1 trial results show promising response rates, which could potentially boost investor confidence and the company's stock price.
The reported high response rates from the ANTLER Phase 1 trial indicate that Caribou Biosciences' CB-010 therapy is effective. This positive news could potentially attract more investors, leading to an increase in the company's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100